# FDA approves new drug for advanced head and neck squamous cell carcinoma

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html) · 2026-11-18 · Medicine
Page: https://themorning.science/story/fda-approves-new-drug-for-advanced-head-and-neck-squamous-cell-carcinoma-2426e741e0c0509b
Kind: other · Impact: medium

## In brief

- The US Food and Drug Administration (FDA) has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) from Janssen Biotech.
- The approval covers adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progressed during or after prior treatment.
- The source article is dated 2026-11-18 and reports the approval; the exact approval date is not stated in the available text.

## Why it matters

It adds an FDA-approved treatment option for a group of advanced head and neck squamous cell carcinoma patients whose disease has progressed, a setting where options are limited.

## Timeline

- 2026-11-18: FDA approval of Rybrevant Faspro for HNSCC reported by Medical Xpress

## Coverage

- [FDA approves new drug for advanced head and neck squamous cell carcinoma](https://medicalxpress.com/news/2026-11-fda-drug-advanced-neck-squamous.html) — Medical Xpress - latest medical and health news stories, 2026-11-18

Tags: fda approval, oncology, head and neck cancer, amivantamab, drug approval

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
